Aquestive Therapeutics (NASDAQ:AQST) Insider Sells $45,675.00 in Stock

Aquestive Therapeutics, Inc. (NASDAQ:AQST) insider Sherry Korczynski sold 8,750 shares of the stock in a transaction on Wednesday, September 9th. The stock was sold at an average price of $5.22, for a total value of $45,675.00. Following the completion of the sale, the insider owned 235,689 shares in the company, valued at $1,230,296.58. This trade represents a 3.58% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Aquestive Therapeutics Price Performance

Aquestive Therapeutics stock opened at $4.78 on Monday. The stock has a market cap of $599.94 million, a price-to-earnings ratio of -7.35 and a beta of 1.48. The business has a 50-day simple moving average of $4.39 and a 200 day simple moving average of $4.26. Aquestive Therapeutics, Inc. has a 52 week low of $2.93 and a 52 week high of $7.55.

Aquestive Therapeutics (NASDAQ:AQST) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.08). The business had revenue of $13.82 million during the quarter, compared to analysts’ expectations of $11.42 million. On average, research analysts anticipate that Aquestive Therapeutics, Inc. will post -0.5 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Bratton Capital Management L.P. bought a new stake in shares of Aquestive Therapeutics in the 2nd quarter worth approximately $40,813,585. BlackRock Inc. purchased a new position in Aquestive Therapeutics in the 2nd quarter worth $33,569,000. Vanguard Group Inc. raised its position in Aquestive Therapeutics by 30.8% in the 3rd quarter. Vanguard Group Inc. now owns 5,662,132 shares of the company’s stock worth $31,651,000 after purchasing an additional 1,333,627 shares during the period. State Street Corp lifted its stake in Aquestive Therapeutics by 53.7% in the fourth quarter. State Street Corp now owns 2,462,778 shares of the company’s stock worth $15,910,000 after purchasing an additional 860,562 shares during the last quarter. Finally, Bank of America Corp DE lifted its stake in Aquestive Therapeutics by 99.2% in the first quarter. Bank of America Corp DE now owns 2,405,050 shares of the company’s stock worth $9,981,000 after purchasing an additional 1,197,459 shares during the last quarter. 32.45% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Wall Street Zen upgraded shares of Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Weiss Ratings reissued a “sell (d-)” rating on shares of Aquestive Therapeutics in a report on Friday, July 17th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Aquestive Therapeutics in a report on Monday, August 24th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $11.00 target price on shares of Aquestive Therapeutics in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Aquestive Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $9.17.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on developing and commercializing medicines delivered through its PharmFilm technology. The company’s dissolvable oral-film platform is designed to provide alternatives to conventional tablets, capsules and injectable therapies, with potential benefits for patients who have difficulty swallowing or require rapid, convenient administration.

Aquestive’s commercial products include Exservan, an oral film formulation of riluzole for people with amyotrophic lateral sclerosis; Libervant, a buccal film formulation of diazepam for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity; and Sympazan, an oral film formulation of clonazepam for the treatment of seizures associated with Lennox-Gastaut syndrome.